Research Article
Intake of Novel Red Clover Supplementation for 12 Weeks Improves Bone Status in Healthy Menopausal Women
Table 2
The baseline characteristics for treatment group (RC) and placebo.
| | | RC () | Placebo () | valuea |
| | Age, years | 52.65 (±0.85) | 52.28 (±0.42) | | | BMI | 26.01 (±0.97) | 25.45 (±0.60) | | | FSH, int.enh./L | 72.74 (±4.88) | 72.07 (±4.85) | | | Family history of osteoporosis (yes/no) | 6/29 | 5/26 | — | | DXA | | | | | BMD lumbar spine, g/cm2 | 1.06 (±0.04) | 1.05 (±0.04) | | | BMD femoral neck, g/cm2 | 0.913 (±0.02) | 0.85 (±0.02) | | | BMC, lumbar spine, g | 50.49 (±2.16) | 48.34 (±1.57) | | | BMC, femoral neck, g | 4.31 (±0.13) | 4.09 (±0.09) | | | -score, lumbar spine, SD | −0.23 (±0.39) | −0.36 (±0.23) | | | -score, femoral neck, SD | −0.06 (±0.20) | −0.57 (±0.17) | | | Biochemical marker | | | | | Ctx ng/mL | 0.48 (±0.05) | 0.54 (±0.03) | | | 24-hour blood pressure | | | | | (i) Systolic mmHg | 125.0 (±1.89) | 124.5 (±2.21) | | | (ii) Diastolic mmHg | 78.9 (±1.36) | 78.2 (±1.26) | |
|
|
Representing value between groups at baseline. Data are presented as mean (±SEM).
|
